Publications

European Urology

Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.

May 2020

Read more

European Urology

Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?

An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.

May 2020

Read more

EBioMedicine

Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.

April 2020

Read more

Chinese Journal of Cancer Research

Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.

February 2020

Read more

Critical Reviews in Oncology

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms. 

January  2020

Read More

BREAST CANCER RESEARCH

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.

December  2019

Read More

Posters

ASCO 2020 Virtual

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)

• ctDNA changes correlate with ORR in BTC patients treated with durvalumab + tremelimumab immunotherapy

• PredicineATLAS™ cfDNA

• Collaboration with AstraZeneca 

May  2020

 

View Poster

AACR - Advances in Liquid Biopsies 2020

Simultaneous Multi-parametric Profiling of cfRNA and ctDNA in Advanced-stage Colorectal Cancer

• ctDNA and cfRNA profiling, TMB

• Matched plasma and tissue

• Collaboration with Merck KGaA and EMD Serono

January  2020

 

 

View Poster

AACR 2020 Virtual

Development of cfDNA-based methylation assay for early cancer detection

• Methylation profiling in plasma cfDNA and urinary cfDNA

• PredicineMETHYLATION™ 

• Early cancer detection

 

June  2020

 

 

 

View Poster

AACR 2020 Virtual

Urine-based molecular biomarker signatures for bladder cancer

• Urinary cfDNA

• TERT, FGFR3, PIK3CA, PIK3CB

• Bladder cancer

June  2020

 

 

View Poster

AACR 2020 Virtual

Combined cell-free DNA and cell-free RNA NGS testing for cancer patient care

• Fusions and splice variants in cfRNA

• PredicineRNA™ 

• NSCLC and mCRPC

June  2020

 

 

View Poster

ASCO 2020 Virtual

Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China

• ctDNA profiling

• HR+ mBC

• PTEN, PIK3CA, TP53, FGFR1

May  2020

 

View Poster

ASCO-GU 2020

Biomarker Analysis (CTC and ctDNA/ctRNA) of GT0918 (Proxalutamide) New AR Blocker in Phase I mCRPC Patients with Dose Escalation

• ctDNA profiling for AR mutation and amplification

• cfRNA profiling for AR-V7 splicing variants

• Therapy response and drug resistance

January 2020

 

View Poster

ASCO-GU 2019

Plasma-based Exploratory Biomarker Analysis to Evaluate GT0918 in a Phase 1/2 Study in mCRPC Patients

• PTEN-PI3K, AR, DDR pathway alterations

• Mono- vs. bi-allelic gene deletion in BRCA, PTEN

• cfRNA-based detection of fusions and splice variants

January 2019

 

View Poster

Abstracts

2019 SABCS

Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance

Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli

December 2019

 

Read more

2019 SABCS

Blood-based detection of PTEN loss and pathway alterations for personalized treatment of breast cancer

Pan Du, Eric Jia and Zhixin Zhao

December 2019

 

Read more

2019 SABCS

Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA

Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli

December 2019

 

Read more

2019 ASCO

Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee

June 2019

 

Read more

2019 AACR

Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy response

Jianjun Yu, Jianguo Dong, Amy Wang, Joseph S. Krueger

April 2019

 

Read more

2019 AACR

Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients

Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad

April 2019

 

Read more

2019 AACR

Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in immuno-oncology

Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du

April 2019

 

Read more

2019 ASCO-GU

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer

Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu

February 2019

 

Read more

2018 SABCS

Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients

Yu J, Li H, Zhang S, Wang A, Zhao Z

December 2018

 

Read more

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.